Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex,